Glutamatergic markers, age, intellectual functioning and psychosis in 22q11 deletion syndrome

RationalePatients with 22q11 deletion syndrome (22q11DS) have a high prevalence of intellectual disabilities and psychiatric disorders, including psychosis. Haplo-insufficiency of genes in the deleted region may offer a partial explanation for the increased vulnerability for psychosis and intellectual disability. One gene of particular interest is the gene coding for proline dehydrogenase (PRODH), an enzyme responsible for the conversion of proline into glutamate.ObjectivesBecause abnormalities in glutamatergic signaling are thought to be responsible for cognition and psychosis in the general population, we hypothesized that PRODH haplo-insufficiency may underlie some of the cognitive and psychotic features seen in 22q11DS.MethodsIn this explorative study, we investigated the relation between plasma proline, glutamate, and glutamine and age, intelligence, and psychosis in 64 adults with 22q11DS.ResultsHyperprolinemia was found in 31.3 % of subjects with 22q11DS. A relation between glutamine, glutamate, proline, and presence of psychosis was not observed. Regression analysis revealed a positive relation between plasma glutamate and age, a positive relation of glutamate with antipsychotic drugs, a relation of glutamine and gender, and a positive relation of glutamine and mood stabilizing drugs, and a negative relation of the ratio glutamine/glutamate and age. The group with relatively lower IQ had higher glutamate levels compared to the group with relatively higher IQ.ConclusionsOur results suggest that 22q11DS is accompanied by abnormalities in glutamatergic metabolism. Future longitudinal studies are needed to further investigate the glutamatergic system in 22q11DS and how this affects the development of cognitive problems and psychopathology.

• Publication year

  2015

• Venue

  Psychopharmacology

• Publication date

  2015-06-10

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/s00213-015-3979-xPMID 26055684PMCID 4537490
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Deletion Syndrome

  2019cited by this paper
• Response to clozapine in a clinically identifiable subtype of schizophrenia.

  2015cited by this paper
• Glutamatergic Neurometabolites in Clozapine-Responsive and -Resistant Schizophrenia

  2015cited by this paper
• Peripheral Glutamate Levels in Schizophrenia: Evidence from a Meta-Analysis

  2014cited by this paper
• Serotonergic, noradrenergic and dopaminergic markers are related to cognitive function in adults with 22q11 deletion syndrome.

  2014cited by this paper
• Clozapine: a review of clinical practice guidelines and prescribing trends

  2014cited by this paper
• Psychopathology in adults with 22q11 deletion syndrome and moderate and severe intellectual disability.

  2014cited by this paper
• Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings.

  2014influential reference
• Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome.

  2014cited by this paper
• Cognitive and behavioral trajectories in 22q11DS from childhood into adolescence: a prospective 6-year follow-up study.

  2013cited by this paper
• Effects of age and sex on the concentrations of glutamate and glutamine in the human brain

  2013cited by this paper
• Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies

  2013cited by this paper
• Copy number variation at 22q11.2: from rare variants to common mechanisms of developmental neuropsychiatric disorders

  2013cited by this paper
• Glutamate changes in healthy young adulthood.

  2013influential reference
• Excitotoxicity: bridge to various triggers in neurodegenerative disorders.

  2013cited by this paper
• Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications.

  2013cited by this paper
• Challenges of brain imaging in psychiatry: understanding brain structure and function in schizophrenia

  2012cited by this paper
• Proline and COMT Status Affect Visual Connectivity in Children with 22q11.2 Deletion Syndrome

  2011cited by this paper
• Chromosome 22q11.2 Deletion Syndrome (DiGeorge Syndrome/Velocardiofacial Syndrome)

  2011cited by this paper
• Neuroradiological and Neurofunctional Examinations for Patients with 22q11.2 Deletion

  2011cited by this paper
• Co‐occurrence of early‐onset Parkinson disease and 22q11.2 deletion syndrome: Potential role for dopamine transporter imaging

  2010cited by this paper
• Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: A preliminary study

  2010cited by this paper
• Glutamate receptors, neurotoxicity and neurodegeneration

  2010cited by this paper
• Neuropathologic features in adults with 22q11.2 deletion syndrome.

  2009cited by this paper
• Proline Affects Brain Function in 22q11DS Children with the Low Activity COMT158 Allele

  2009cited by this paper
• Quantitative UPLC-MS/MS analysis of underivatised amino acids in body fluids is a reliable tool for the diagnosis and follow-up of patients with inborn errors of metabolism.

  2009cited by this paper
• Wechsler Adult Intelligence Scale–Third Edition

  2008cited by this paper
• Peripheral Amino Acid Levels in Schizophrenia and Antipsychotic Treatment

  2008cited by this paper
• Chromosome 22q11.2 deletion syndrome: DiGeorge syndrome/velocardiofacial Syndrome.

  2008cited by this paper
• Prevalence of 22q11.2 deletions in 311 Dutch patients with schizophrenia.

  2008cited by this paper
• Regional variations and the effects of age and gender on glutamate concentrations in the human brain.

  2008cited by this paper
• Laboratory guide to the methods in biochemical genetics

  2008cited by this paper
• Vineland Screener 0-6 jaar. Handleiding

  2008cited by this paper
• Involvement of hyperprolinemia in cognitive and psychiatric features of the 22q11 deletion syndrome.

  2007cited by this paper
• Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review

  2007cited by this paper
• Alterations in serum amino acid concentrations in male and female schizophrenic patients.

  2007cited by this paper
• Hyperprolinemia is a risk factor for schizoaffective disorder

  2005influential reference
• Age-related glutamate and glutamine concentration changes in normal human brain: 1H MR spectroscopy study at 4 T.

  2005cited by this paper
• 22q11 deletion syndrome in childhood onset schizophrenia: an update

  2004cited by this paper
• Assessment of the frequency of the 22q11 deletion in Afrikaner schizophrenic patients

  2004cited by this paper
• Glutamate and the glutamate receptor system: a target for drug action

  2003cited by this paper
• Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine.

  2002cited by this paper
• Beyond the role of glutamate as a neurotransmitter

  2002cited by this paper
• Reliability and validity of the Mini PAS-ADD for assessing psychiatric disorders in adults with intellectual disability.

  2002influential reference
• PRODH mutations and hyperprolinemia in a subset of schizophrenic patients.

  2002cited by this paper
• Hyperprolinaemia in patients with deletion (22)(q11.2) syndrome

  2000cited by this paper
• High rates of schizophrenia in adults with velo-cardio-facial syndrome.

  1999cited by this paper
• The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

  1998cited by this paper
• The mini international neuropsychiatric interview

  1998cited by this paper
• The neurobiological basis of prefrontal cortex self-stimulation: a review and an integrative hypothesis.

  1990cited by this paper
• Relationships between glutamate and monoamine metabolites in cerebrospinal fluid and serum in healthy volunteers.

  1988cited by this paper
• Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity.

  1988cited by this paper
• PSYCHOPHARMACOLOGY

  1957cited by this paper

• Neural excitation/inhibition imbalance and neurodevelopmental pathology in human copy number variant syndromes: a systematic review

  2025influential citation
• Unravelling the role of Neurotrimin (NTM), a member of the IgLON family, in mild intellectual disability and anxiety-like behaviors.

  2025cites this paper
• Longitudinal Analysis of Brain Function-Structure Dependencies in 22q11.2DS and Psychotic Symptoms.

  2024cites this paper
• Profiling of Long Non-Coding RNAs in Auricular Cartilage of Patients with Isolated Microtia

  2024cites this paper
• The Relationships between Dopaminergic, Glutamatergic, and Cognitive Functioning in 22q11.2 Deletion Syndrome: A Cross-Sectional, Multimodal 1H-MRS and 18F-Fallypride PET Study

  2022cites this paper
• Excitatory inhibitory imbalance underlies hippocampal atrophy in individuals with 22q11.2 Deletion Syndrome with psychotic symptoms

  2022cites this paper
• Psychiatric phenotypes associated with hyperprolinemia: A systematic review

  2021influential citation
• Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study

  2020cites this paper
• The 22q11.2 Microdeletion in Pediatric Patients with Cleft Lip, Palate, or Both and Congenital Heart Disease: A Systematic Review

  2019cites this paper
• Abnormal development of early auditory processing in 22q11.2 Deletion Syndrome

  2019cites this paper
• A pilot study on machine learning approach to delineate metabolic signatures in intellectual disability

  2019cites this paper
• Riluzole effectively treats psychotic symptoms and improves cognition in 22q11.2 deletion syndrome: A clinical case.

  2019cites this paper
• Neurobiological perspective of 22q11.2 deletion syndrome.

  2019cites this paper
• Glutamatergic function in a genetic high-risk group for psychosis: A proton magnetic resonance spectroscopy study in individuals with 22q11.2 deletion.

  2019cites this paper
• Deletion size analysis of 1680 22q11.2DS subjects identifies a new recombination hotspot on chromosome 22q11.2

  2018cites this paper
• Decreased Serum Glutamate Levels in Male Adults with Internet Gaming Disorder: A Pilot Study

  2018cites this paper
• The use of two different MLPA kits in 22q11.2 deletion syndrome.

  2016cites this paper